Catalyst Wire Dossier Catalyst Wire Dossier

Recombinant hypoallergenic derivative immunotherapy

· Allergopharma GmbH & Co. KG
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Recombinant hypoallergenic derivative immunotherapy, covering 2013-11-08 to 2013-11-08. Get the full timeline:

Most recent: Clinical Trial Update: Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic Derivative [Phase 2]

See pricing